Skip to main content

Market Overview

PPD: Q4 Earnings Insights


Shares of PPD (NASDAQ:PPD) were flat in after-market trading after the company reported Q4 results.

Quarterly Results

Earnings per share increased 18.18% over the past year to $0.39, which beat the estimate of $0.36.

Revenue of $1,364,000,000 rose by 30.28% year over year, which beat the estimate of $1,280,000,000.


The upcoming fiscal year's EPS expected to be between $1.37 and $1.45.

The upcoming fiscal year's revenue expected to be between $5,145,000,000 and $5,304,000,000.

Price Action

Company's 52-week high was at $38.76

52-week low: $10.61

Price action over last quarter: Up 9.56%

Company Description

PPD is a global contract research organization that provides clinical trial and laboratory services to pharmaceutical, device, and diagnostic firms. The clinical development services segment offers outsourced trial services, spanning early- and late-stage trials, as well as peri- and post-approval trials, and the laboratory services segment includes both advanced lab testing and central lab services. The company was taken private in 2011 and went public again in 2020.


Related Articles (PPD)

View Comments and Join the Discussion!

Posted-In: BZI-RecapsEarnings